BioMarin

US-based BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is navigating a challenging period marked by difficulties in commercializing its gene therapies. In a recent SEC filing, the company announced plans to reduce its workforce by 225 employees as part of its “organizational redesign efforts.” The restructuring is tied to BioMarin’s revised commercial…